- Home
- »
- Our Products
- »
Pharmaceutical Injection
We are a leading Manufacturer of mounjaro (tirzepatide) injection 2.5mg 4 pens per box, kuwait, mounjaro tirzepatide injection 2.5 mg, 5mg, 7.5mg,10mg, 12.5 mg, 15mg, mounjaro tirzepatide injection, 7.5 mg, mounjaro (tirzepatide) 7.5mg/0.5ml, packaging size: 4 prefilled pens, mounjaro (tirzepatide) injection, 2.5 mg ,5 mg,7.5 mg ,10 mg 15 mg and weight lost mounjaro tirzepatide injection,, 2.5 mg from Vadodara, India.Mounjaro (Tirzepatide) Injection 2.5mg 4 Pens per Box, Kuwait
Product Details:
| Strength | 2.5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Pre-filled pen |
| Brand | Mounjaro |
| Manufacturer | Mounjaro |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Callback
Mounjaro Tirzepatide Injection 2.5 mg, 5mg, 7.5mg,10mg, 12.5 mg, 15mg
Product Details:
| Strength | 2.5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Pre-filled pen |
| Brand | Mounjaro |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Callback
Mounjaro Tirzepatide Injection, 7.5 mg
Product Details:
| Strength | 7.5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Pre-filled pen |
| Brand | Mounjaro |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Callback
Mounjaro (Tirzepatide) 7.5mg/0.5ml, Packaging Size: 4 Prefilled Pens
Product Details:
| Strength | 7.5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Pre-filled pen |
| Brand | Mounjaro |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Callback
Mounjaro (Tirzepatide) Injection, 2.5 Mg ,5 Mg,7.5 Mg ,10 Mg 15 Mg
Product Details:
| Strength | 2.5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Pre-filled pen |
| Brand | Mounjaro |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Callback
Weight Lost Mounjaro Tirzepatide Injection,, 2.5 mg
Product Details:
| Strength | 2.5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Pre-filled pen |
| Brand | Mounjaro |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Callback
Saxenda 18 mg/3 mL (6 mg/mL) pre-filled pen
Product Details:
| Strength | 6 mg/ ml |
| Packaging Type | Box |
| Brand | Saxenda |
Saxenda® (liraglutide) injection 3 mg is an injectable prescription medicine used for adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30), and children aged 12-17 years with a body weight above 132 pounds (60 kg) and obesity to help them lose weight and keep the weight off. Saxenda® should be used with a reduced calorie diet and increased physical activity.
- Saxenda® and Victoza® have the same active ingredient, liraglutide, and should not be used together or with other GLP-1 receptor agonist medicines
- It is not known if Saxenda® is safe and effective when taken with other prescription, over-the-counter medicines, or herbal weight-loss products
- It is not known if Saxenda® is safe and effective in children under 12 years of age
- It is not known if Saxenda® is safe and effective in children aged 12 to 17 years with type 2 diabetes
Callback
Mounjaro Tirzepatide 5 mg Injection DENMARK DELIVERY
Product Details:
| Strength | 5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Injection |
| Brand | Mounjaro |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Callback
MOUNJARO TIRZEPATIDE INJECTION 7.5mg Us-us Delivery
Product Details:
| Strength | 7.5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Injection |
| Brand | MOUNJARO |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Callback
Mounjaro (Tirzepatide) 7.5mg/0.5mL Pre-filled 4 Pens
Product Details:
| Strength | 7.5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Injection |
| Brand | Mounjaro |
Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.
Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.
Callback
Saxenda 6 Mg Ml Injection For Clinical ( CANADA FAST DELIVERY )
Product Details:
| Strength | 6 mg/ ml |
| Packaging Type | Box |
Saxenda® (liraglutide) injection 3 mg is an injectable prescription medicine used for adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30), and children aged 12-17 years with a body weight above 132 pounds (60 kg) and obesity to help them lose weight and keep the weight off. Saxenda® should be used with a reduced calorie diet and increased physical activity.
Saxenda® and Victoza® have the same active ingredient, liraglutide, and should not be used together or with other GLP-1 receptor agonist medicines
It is not known if Saxenda® is safe and effective when taken with other prescription, over-the-counter medicines, or herbal weight-loss products
It is not known if Saxenda® is safe and effective in children under 12 years of age
It is not known if Saxenda® is safe and effective in children aged 12 to 17 years with type 2 diabetes
Callback
Saxenda 6 Mg/ Ml 5 Pre-Filled Pen
Product Details:
| Strength | 6 mg/ ml |
| Packaging Type | Box |
Saxenda® (liraglutide) injection 3 mg is an injectable prescription medicine used for adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30), and children aged 12-17 years with a body weight above 132 pounds (60 kg) and obesity to help them lose weight and keep the weight off. Saxenda® should be used with a reduced calorie diet and increased physical activity.
- Saxenda® and Victoza® have the same active ingredient, liraglutide, and should not be used together or with other GLP-1 receptor agonist medicines
- It is not known if Saxenda® is safe and effective when taken with other prescription, over-the-counter medicines, or herbal weight-loss products
- It is not known if Saxenda® is safe and effective in children under 12 years of age
- It is not known if Saxenda® is safe and effective in children aged 12 to 17 years with type 2 diabetes
Callback
